BofA analyst Tazeen Ahmad raised the firm’s price target on BioCryst (BCRX) to $13 from $11 and keeps a Buy rating on the shares. BioCryst reported Q1 Orladeyo revenue slightly above Street expectations and Orladeyo FY25 revenue guidance was increased to $580M-$600M, notes the analyst. The firm remains encouraged by the strong commercial trajectory that somewhat derisks their $1B revenue goal by 2030 and now models peak sales of $723M in 2028, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst’s Strong Growth Prospects: Buy Rating Backed by Orladeyo’s Success and Promising Pipeline Developments
- BioCryst Pharmaceuticals Reports Strong Q1 2025 Growth
- BioCryst Pharmaceuticals Reports Record Growth and Profitability
- Strong Growth Prospects for BioCryst’s Orladeyo Drive Buy Rating and Increased Price Target
- BioCryst’s Orladeyo Surpasses Expectations: A Strong Buy Recommendation